NCT03284164

Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex

An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: ContraVir Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1 study to investigate the effects of Renal Impairment on the pharmacokinetics of Tenofovir exalidex

Detailed description

This is a Phase 1 study to investigate the effects of Renal Impairment (mild, moderate and severe) on the pharmacokinetics of Tenofovir Exalidex

Conditions

• Renal Impairment

Interventions

Type	Name	Description
DRUG	Tenofovir Exalidex (TXL)	Drug: Tenofovir Exalidex (TXL)

Timeline

• Start date: 2017-09-28
• Primary completion: 2018-01-17
• Completion: 2018-02-20
• First posted: 2017-09-15
• Last updated: 2018-06-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study